HRP20211418T1 - Čestice polimera i njihova uporaba - Google Patents
Čestice polimera i njihova uporaba Download PDFInfo
- Publication number
- HRP20211418T1 HRP20211418T1 HRP20211418TT HRP20211418T HRP20211418T1 HR P20211418 T1 HRP20211418 T1 HR P20211418T1 HR P20211418T T HRP20211418T T HR P20211418TT HR P20211418 T HRP20211418 T HR P20211418T HR P20211418 T1 HRP20211418 T1 HR P20211418T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- binding
- domain capable
- binding domain
- rv3615c
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 27
- 229920000642 polymer Polymers 0.000 title claims 18
- 239000000427 antigen Substances 0.000 claims 103
- 102000036639 antigens Human genes 0.000 claims 103
- 108091007433 antigens Proteins 0.000 claims 103
- 101100445609 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) espC gene Proteins 0.000 claims 19
- 101150079015 esxB gene Proteins 0.000 claims 19
- 101100389765 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) esxS gene Proteins 0.000 claims 17
- 101100389755 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) esxO gene Proteins 0.000 claims 12
- 230000004927 fusion Effects 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000008827 tuberculosis Diseases 0.000 claims 9
- 241000186366 Mycobacterium bovis Species 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000012296 in situ hybridization assay Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- -1 preparation Substances 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
Claims (15)
1. Polimerna čestica sadrži jedan ili više polipeptida fuzije, pri čemu jedan ili više polipeptida fuzije sadrži:
(A) proteinom stvorenu česticu i dvije ili više iz te skupine koja sadrži
a. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen,
b. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen,
c. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen, i
d. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen, ili
(B) proteinom stvorenu česticu i tri ili više iz te skupine koja sadrže
a. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen;
b. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen,
c. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen,
d. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen, i
e. Rv2346c antigen ili veznu domenu sposobnu vezati Rv2346c antigen, ili
(C) proteinom stvorenu česticu, ESAT6 antigen, CFP10 antigen, i Rv3615c antigen, ili
(D) proteinom stvorenu česticu, ESAT6 antigen, CFP10 antigen, i Rv3615c antigen, pri čemu spomenuti polipeptid fuzije ima najmanje oko 95% jednakost sekvence sa sekvencom aminokiseline prikazanom na SEK. ID. BR. 10, ili
(E) protein stvarajuća čestica i
i. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen; i
ii. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen; i
iii. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen, i
iv. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen, ili
(F) protein stvarajuća čestica, ESAT6 antigen, CFP10 antigen, i Rv3615c antigen, i Rv3020c antigen.
2. Polimerna čestica sukladno patentnom zahtjevu 1, pri čemu ta čestica polimera sadrži najmanje jedan polipeptid fuzije koja koja sadrži proteinom stvorenu česticu i dvije ili više skupina koje sadrže
i. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen;
ii. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen;
iii. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen;
iv. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen; i
v. Rv2346c antigen ili veznu domenu sposobnu vezati Rv2346c antigen;
i najmanje jedan polipeptid fuzije koja sadrži proteinom stvorenu česticu i jednu ili više skupina koje sadrže
vi. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen;
vii. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen;
viii. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen;
ix. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen; i
x. Rv2346c antigen ili veznu domenu sposobnu vezati Rv2346c antigen.
3. Čestica polimera sukladno patentnom zahtjevu 2., pri čemu polipeptid fuzije sadrži jedan ili više antigena koja skupina (vi) do (x) je različita u odnosu na polipeptid fuzije koja sadrži dva ili više antigena iz skupine (i) do (v).
4. Čestica polimera sukladno bilo kojem od patentnih zahtjeva 1. do 3., pri čemu kada je prisutan ESAT6 antigen sadrži 10. ili više dodirnih aminokiselina iz sekvence aminokiselina sukladno SEK. ID. br. 1., i kada je prisutan CFP10 antigen sadrži 10. ili više dodirnih aminokiselina iz sekvence aminokiselina sukladno SEK. ID. br. 2., i kada je prisutan Rv3615c antigen sadrži 10. ili više dodirnih aminokiselina iz sekvence aminokiselina sukladno SEK. ID. br. 3., i kada je prisutan Rv3020c antigen sadrži 10 ili više dodirnih aminokiselina iz sekvencije aminokiselina sukladno SEK. ID. br. 4., i kada je prisutan Rv2346c antigen sadrži 10 ili više dodirnih aminokiselina iz sekvencije aminokiselina SEK. ID. br. 5.
5. Čestica polimera sukladno patentnom zahtjevu 4., pri čemu kada je prisutan ESAT6 antigen sadrži sekvencu aminokiseline SEK. ID. br. 1., i kada je prisutan CFP10 antigen sadrži sekvencu aminokiselina sukladno SEK. ID. br. 2., i kada je prisutan Rv3615c antigen sadrži sekvencu aminokiselina sukladno SEK. ID. br. 3., i kada je prisutan Rv3020c antigen sadrži sekvencu aminokisleina SEK. ID. br. 4., i kada je prisutan Rv2346c antigen sadrži sekvencu aminokiselina SEK. ID. br. 5.
6. Pripravak koja sadrži jednu ili više čestica polimera sukladno bilo kojem od patentnih zahtjeva 1. do 5., i nosač.
7. Pripravak sukladno patentnom zahtjevu 6. pri čemu taj pripravak sadrži dvije ili više populacija čestica polimera, pri čemu jedna populacija čestica polimera sadrži jedan ili više polipeptida fuzije sadrži proteinom stvorenu česticu i dvije ili više skupina koje sadrže
i. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen;
ii. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen;
iii. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen;
iv. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen; i
v. Rv2346c antigen ili veznu domenu sposobnu vezati Rv2346c antigen;
i jedna populacija čestica polimera sadrži jedan ili više polipeptida fuzije sadrži proteinom stvorenu česticu i jednu ili više skupina koja sadrži
vi. ESAT6 antigen ili veznu domenu sposobnu vezati ESAT6 antigen;
vii. CFP10 antigen ili veznu domenu sposobnu vezati CFP10 antigen;
viii. Rv3615c antigen ili veznu domenu sposobnu vezati Rv3615c antigen;
ix. Rv3020c antigen ili veznu domenu sposobnu vezati Rv3020c antigen; i
x. Rv2346c antigen ili veznu domenu sposobnu vezati Rv2346c antigen;
pri čemu je jedan ili više polipeptida fuzije prisutnih na jednoj populaciji čestica polimera drugačiji na jednom ili više polipeptida fuzije prisutnih na jednoj drugoj populaciji čestica polimera.
8. Dijagnostički reagens koja sadrži jednu ili više čestica polimera sukladno bilo kojem od patentnih zahtjeva 1. do 5. ili pripravak za koju se zaštita patentom traži u patentnim zahtjevima 6. ili 7., poželjno za topikalnu primjenu pacijentu.
9. Dijagnostički reagens sukladno patentnog zahtjeva 8., pri čemu dijagnostički reagens
(A) je stvoren da bi osigurao manje od 10 mikrograma ukupnog antigena po dozi,
(B) sadrži manje od 5 µg ukupnog antigena po dozi,
(C) se stvara da bi se osiguralo manje od 5 µg jednog ili više antigena prisutnih po dozi,
(D) se stvara da bi se osiguralo manje od 1 µg jednog ili više antigena prisutnih po dozi,
(E) se stvara da bi se osiguralo manje od 5 µg svakog antigena prisutnog po dozi,
(F) sadrži manje od 5 µg svakog antigena prisutnog po dozi,
(G) sadrži manje od 1 µg svakog antigena prisutnog po dozi,
(H) sadrži manje od 0,5 µg jednog ili više antigena prisutnih po dozi,
(I) sadrži manje od 0,5 µg svakog antigena prisutnog po dozi,
(J) sadrži manje od 50 ng svakog antigena prisutnog po dozi,
(K) je stvoren da osigura manje od 50 ng ukupnog antigena po dozi, ili
(L) je stvoren da osigura manje od 10 ng ukupnog antigena po dozi.
10. Najmanje jedna čestica polimera sukladno bilo kojem od patentnih zahtjeva 1. do 5., pripravak sukladno patentnom zahtjevu 6. ili 7., ili reagens sukladno patentnom zahtjevu 8. ili 9., za uporabu u postupku dijagnosticiranja tuberkuloze kod subjekta, taj postupak sadrži isporuku subjektu učinkovite količine najmanje jedne čestice polimera sukladno bilo kojem od patentnih zahtjeva 1. do 5., pripravka sukladno patentnom zahtjevu 6. ili 7., ili reagensa sukladno patentnom zahtjevu 8. ili 9., i
utvrđivanje odgovora imunosnog sustava kod subjekta, pri čemu je prisutnost odgovora imunosnog sustava indikativno za tuberkulozu.
11. Najmanje jedna čestica polimera, pripravak, ili reagens za uporabu sukladno patentnom zahtjevu 10, pri čemu je primjena topikalna, poželjno putem uboda u kožu.
12. Postupak dijagnosticiranja M. tuberculosis ili M. bovis u uzorku od subjekta, taj postupak sadrži
osiguravanje uzorka iz subjekta,
dovođenje u dodir uzorka s najmanje jednom česticom polimera sukladno bilo kojem od patentnih zahtjeva 1. do 5., pripravkom sukladno patentnom zahtjevu 6. ili 7., ili reagensom sukladno patentnom zahtjevu 8. ili 9., i otkrivanje odgovora indikativnog za prisutnost jednog ili više M. tuberculosis antigena u tome uzorku,
pri čemu je taj odgovor indikativan na prisutnost jednog ili više M. tuberculosis ili M. bovis antigena je indikativan za M. tuberculosis ili M. bovis kod tog subjekta.
13. Postupak sukladno patentnom zahtjevu 12., pri čemu je odgovor indikativan na prisutnost jednog ili više M. tuberculosis ili M. bovis antigena je
(A) otkrivanje prisutnosti antitijela na M. tuberculosis ili M. bovis u navedenom uzorku, ili
(B) otkrivanje prisutnosti imunosne stanice koja reagira na M. tuberculosis ili M. bovis u navedenom uzorku.
14. Postupak sukladno patentnom zahtjevu 12 ili 13, pri čemu je to otkrivanje putem imunoogleda, putem ELISA, radioimunoogleda, ili Western Blot putem ogleda citokina, ili je gama interferonom.
15. Postupak sukladno patentnom zahtjevu 13, pri čemu prisutnost imunosne stanice koja reagira na Mycobacterium tuberculosis ili M. bovis se otkriva ogledom proliferacije stanice, ogledom sortiranja stanice uključujući FACS, ili ogledom hibridsukladnoacije in situ.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ62068214 | 2014-02-04 | ||
| EP15746012.2A EP3102613B1 (en) | 2014-02-04 | 2015-02-04 | Polymer particles and uses thereof |
| PCT/NZ2015/050008 WO2015119512A1 (en) | 2014-02-04 | 2015-02-04 | Polymer particles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211418T1 true HRP20211418T1 (hr) | 2021-12-24 |
Family
ID=53778236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211418TT HRP20211418T1 (hr) | 2014-02-04 | 2015-02-04 | Čestice polimera i njihova uporaba |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10501505B2 (hr) |
| EP (1) | EP3102613B1 (hr) |
| CY (1) | CY1124491T1 (hr) |
| DK (1) | DK3102613T3 (hr) |
| ES (1) | ES2891973T3 (hr) |
| HK (1) | HK1232241A1 (hr) |
| HR (1) | HRP20211418T1 (hr) |
| HU (1) | HUE056108T2 (hr) |
| LT (1) | LT3102613T (hr) |
| PL (1) | PL3102613T3 (hr) |
| RS (1) | RS62375B1 (hr) |
| SI (1) | SI3102613T1 (hr) |
| WO (1) | WO2015119512A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018111536A1 (en) | 2016-12-14 | 2018-06-21 | Becton, Dickinson And Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| CN109776661B (zh) * | 2019-03-13 | 2022-08-09 | 中国动物卫生与流行病学中心 | 一种牛结核病γ-干扰素ELISA检测用鸡尾酒刺激抗原 |
| CN109776662B (zh) * | 2019-03-13 | 2022-05-17 | 中国动物卫生与流行病学中心 | 一种用于牛结核病变态反应检测的鸡尾酒抗原 |
| CN109813884A (zh) * | 2019-03-25 | 2019-05-28 | 中国动物卫生与流行病学中心 | 一种牛结核病γ-干扰素快速检测制品 |
| CN109813576B (zh) * | 2019-03-25 | 2021-04-02 | 中国动物卫生与流行病学中心 | 一种牛结核病刺激上清制备用采血器 |
| CN111269297B (zh) * | 2020-01-23 | 2021-11-30 | 郑州伊美诺生物技术有限公司 | 一种结核分枝杆菌刺激抗原的制备方法 |
| EP4132952A4 (en) * | 2020-04-08 | 2024-10-02 | Nanopin Tech Inc | MONOCLONAL ANTIBODIES AND USES THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US7037510B2 (en) | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
| US20060024332A1 (en) * | 2004-08-02 | 2006-02-02 | Waters Wade R | Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis |
| DK1929010T3 (en) * | 2005-09-27 | 2014-03-10 | Polybatics Ltd | Use of the polymer particles |
| JP2013500329A (ja) * | 2009-07-29 | 2013-01-07 | ヘルムート アダム レフム ベルン | ポリマー粒子およびその使用 |
| WO2012104791A1 (en) * | 2011-02-01 | 2012-08-09 | Bernd Helmut Adam Rehm | Fusion polypeptides and uses thereof |
| WO2014009439A1 (en) * | 2012-07-10 | 2014-01-16 | Nec Europe Ltd. | Reporting user related information in a mobile communication network |
-
2015
- 2015-02-04 SI SI201531698T patent/SI3102613T1/sl unknown
- 2015-02-04 EP EP15746012.2A patent/EP3102613B1/en active Active
- 2015-02-04 DK DK15746012.2T patent/DK3102613T3/da active
- 2015-02-04 ES ES15746012T patent/ES2891973T3/es active Active
- 2015-02-04 RS RS20211112A patent/RS62375B1/sr unknown
- 2015-02-04 LT LTEPPCT/NZ2015/050008T patent/LT3102613T/lt unknown
- 2015-02-04 WO PCT/NZ2015/050008 patent/WO2015119512A1/en active Application Filing
- 2015-02-04 HU HUE15746012A patent/HUE056108T2/hu unknown
- 2015-02-04 US US15/116,338 patent/US10501505B2/en active Active
- 2015-02-04 PL PL15746012T patent/PL3102613T3/pl unknown
- 2015-02-04 HR HRP20211418TT patent/HRP20211418T1/hr unknown
-
2017
- 2017-06-14 HK HK17105924.1A patent/HK1232241A1/zh unknown
-
2021
- 2021-09-09 CY CY20211100798T patent/CY1124491T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3102613A1 (en) | 2016-12-14 |
| DK3102613T3 (da) | 2021-09-13 |
| LT3102613T (lt) | 2021-09-27 |
| HK1232241A1 (zh) | 2018-01-05 |
| PL3102613T3 (pl) | 2021-12-13 |
| EP3102613A4 (en) | 2017-12-20 |
| EP3102613B1 (en) | 2021-06-09 |
| CY1124491T1 (el) | 2022-07-22 |
| ES2891973T3 (es) | 2022-02-01 |
| SI3102613T1 (sl) | 2021-11-30 |
| WO2015119512A1 (en) | 2015-08-13 |
| RS62375B1 (sr) | 2021-10-29 |
| HUE056108T2 (hu) | 2022-01-28 |
| US20170008938A1 (en) | 2017-01-12 |
| US10501505B2 (en) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211418T1 (hr) | Čestice polimera i njihova uporaba | |
| Russell et al. | Compromised metabolic reprogramming is an early indicator of CD8+ T cell dysfunction during chronic Mycobacterium tuberculosis infection | |
| Shafeque et al. | Fourth-generation QuantiFERON-TB Gold Plus: what is the evidence? | |
| Klug‐Micu et al. | CD40 ligand and interferon‐γ induce an antimicrobial response against M ycobacterium tuberculosis in human monocytes | |
| Cherukuri et al. | Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein | |
| Crucian et al. | Immune system dysregulation occurs during short duration spaceflight on board the space shuttle | |
| Dalley et al. | Development and evaluation of a gamma-interferon assay for tuberculosis in badgers (Meles meles) | |
| de Cassan et al. | Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A | |
| Welsh et al. | Responses of bovine WC1+ γδ T cells to protein and nonprotein antigens of Mycobacterium bovis | |
| Hughes et al. | Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry | |
| Arroyo et al. | Multifunctional T cell response to DosR and Rpf antigens is associated with protection in long-term Mycobacterium tuberculosis-infected individuals in Colombia | |
| Tanner et al. | Tools for assessing the protective efficacy of TB vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection | |
| Guerra-Maupome et al. | Characterization of γδ T cell effector/memory subsets based on CD27 and CD45R expression in response to Mycobacterium bovis infection | |
| Buddle et al. | Evaluation of a commercial enzyme-linked immunosorbent assay for the diagnosis of bovine tuberculosis from milk samples from dairy cows | |
| CN102818889A (zh) | 检测结核杆菌脂阿拉伯甘露聚糖特异性抗体的方法 | |
| US8865422B2 (en) | Method for the diagnosis of tuberculosis | |
| Maue et al. | Analysis of immune responses directed toward a recombinant early secretory antigenic target six-kilodalton protein-culture filtrate protein 10 fusion protein in Mycobacterium bovis-infected cattle | |
| Asplund Högelin et al. | B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients | |
| Grøndahl-Rosado et al. | NCR1 is an activating receptor expressed on a subset of canine NK cells | |
| Elnaggar et al. | Development of an improved ESAT-6 and CFP-10 peptide-based cytokine flow cytometric assay for bovine tuberculosis | |
| Agallou et al. | Transcriptome analysis identifies immune markers related to visceral leishmaniasis establishment in the experimental model of BALB/c mice | |
| Mannering et al. | T‐cell activation, proliferation and apoptosis in primary Listeria monocytogenes infection | |
| Sivakumaran et al. | A 2-dose AERAS-402 regimen boosts CD8+ Polyfunctionality in HIV-negative, BCG-vaccinated recipients | |
| Parsons et al. | The kinetics of the humoral and interferon-gamma immune responses to experimental Mycobacterium bovis infection in the white rhinoceros (Ceratotherium simum) | |
| Hasan et al. | Mycobacterium tuberculosis Sonicate–Induced IFNγ, CXCL10 and IL10 can Differentiate Severity in Tuberculosis |